These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38222827)

  • 1. National Hepatitis C estimates: Incidence, prevalence, undiagnosed proportion and treatment, Canada, 2019.
    Popovic N; Williams A; Périnet S; Campeau L; Yang Q; Zhang F; Yan P; Feld J; Janjua N; Klein M; Krajden M; Wong W; Cox J
    Can Commun Dis Rep; 2022 Nov; 48(11-12):540-549. PubMed ID: 38222827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimated prevalence of Hepatitis C Virus infection in Canada, 2011.
    Trubnikov M; Yan P; Archibald C
    Can Commun Dis Rep; 2014 Dec; 40(19):429-436. PubMed ID: 29769874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies.
    Sacks-Davis R; van Santen DK; Boyd A; Young J; Stewart A; Doyle JS; Rauch A; Mugglin C; Klein M; van der Valk M; Smit C; Jarrin I; Berenguer J; Lacombe K; Requena MB; Wittkop L; Leleux O; Bonnet F; Salmon D; Matthews GV; Guy R; Martin NK; Spelman T; Prins M; Stoove M; Hellard M;
    Lancet HIV; 2024 Feb; 11(2):e106-e116. PubMed ID: 38224708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C prevalence and key population size estimate updates in San Francisco: 2015 to 2019.
    Facente SN; Grinstein R; Bruhn R; Kaidarova Z; Wilson E; Hecht J; Burk K; Grebe E; Morris MD
    PLoS One; 2022; 17(5):e0267902. PubMed ID: 35544483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression.
    Kondili LA; Andreoni M; Alberti A; Lobello S; Babudieri S; Roscini AS; Merolla R; Marrocco W; Craxì A
    Epidemics; 2021 Mar; 34():100442. PubMed ID: 33607538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mathematical model by route of transmission and fibrosis progression to estimate undiagnosed individuals with HCV in different Italian regions.
    Kondili LA; Andreoni M; Alberti A; Lobello S; Babudieri S; De Michina A; Merolla R; Marrocco W; Craxì A
    BMC Infect Dis; 2022 Jan; 22(1):58. PubMed ID: 35038987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of hepatitis C virus estimates of undiagnosed individuals in different Italian regions: a mathematical modelling approach by route of transmission and fibrosis progression with results up to January 2021.
    Kondili LA; Andreoni M; Aghemo A; Mastroianni CM; Merolla R; Gallinaro V; Craxì A
    New Microbiol; 2022 Dec; 45(4):249-259. PubMed ID: 36066213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
    Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L
    J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic overview of hepatitis C infection in the Middle East and North Africa.
    Chaabna K; Cheema S; Abraham A; Alrouh H; Lowenfels AB; Maisonneuve P; Mamtani R
    World J Gastroenterol; 2018 Jul; 24(27):3038-3054. PubMed ID: 30038471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montréal, Canada.
    Godin A; Kronfli N; Cox J; Alary M; Maheu-Giroux M
    Int J Drug Policy; 2021 Feb; 88():102738. PubMed ID: 32278651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030.
    Bruggmann P; Blach S; Deltenre P; Fehr J; Kouyos R; Lavanchy D; Müllhaupt B; Rauch A; Razavi H; Schmid P; Semela D; Stoeckle M; Negro F
    Swiss Med Wkly; 2017; 147():w14543. PubMed ID: 29120012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol).
    Hickman M; Dillon JF; Elliott L; De Angelis D; Vickerman P; Foster G; Donnan P; Eriksen A; Flowers P; Goldberg D; Hollingworth W; Ijaz S; Liddell D; Mandal S; Martin N; Beer LJZ; Drysdale K; Fraser H; Glass R; Graham L; Gunson RN; Hamilton E; Harris H; Harris M; Harris R; Heinsbroek E; Hope V; Horwood J; Inglis SK; Innes H; Lane A; Meadows J; McAuley A; Metcalfe C; Migchelsen S; Murray A; Myring G; Palmateer NE; Presanis A; Radley A; Ramsay M; Samartsidis P; Simmons R; Sinka K; Vojt G; Ward Z; Whiteley D; Yeung A; Hutchinson SJ
    BMJ Open; 2019 Sep; 9(9):e029538. PubMed ID: 31551376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model.
    Binka M; Janjua NZ; Grebely J; Estes C; Schanzer D; Kwon JA; Shoukry NH; Kwong JC; Razavi H; Feld JJ; Krajden M
    JAMA Netw Open; 2020 May; 3(5):e204192. PubMed ID: 32374397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
    Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ
    J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.
    Stone J; Martin NK; Hickman M; Hutchinson SJ; Aspinall E; Taylor A; Munro A; Dunleavy K; Peters E; Bramley P; Hayes PC; Goldberg DJ; Vickerman P
    Addiction; 2017 Jul; 112(7):1302-1314. PubMed ID: 28257600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis.
    Artenie A; Stone J; Fraser H; Stewart D; Arum C; Lim AG; McNaughton AL; Trickey A; Ward Z; Abramovitz D; Alary M; Astemborski J; Bruneau J; Clipman SJ; Coffin CS; Croxford S; DeBeck K; Emanuel E; Hayashi K; Hermez JG; Low-Beer D; Luhmann N; Macphail G; Maher L; Palmateer NE; Patel EU; Sacks-Davis R; Van Den Boom W; van Santen DK; Walker JG; Hickman M; Vickerman P;
    Lancet Gastroenterol Hepatol; 2023 Jun; 8(6):533-552. PubMed ID: 36996853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revealing geographical and population heterogeneity in HIV incidence, undiagnosed HIV prevalence and time to diagnosis to improve prevention and care: estimates for France.
    Marty L; Cazein F; Panjo H; Pillonel J; Costagliola D; Supervie V;
    J Int AIDS Soc; 2018 Mar; 21(3):e25100. PubMed ID: 29603879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study.
    Isfordink CJ; Boyd A; Sacks-Davis R; van Santen DK; Smit C; Martinello M; Stoove M; Berenguer J; Wittkop L; Klein MB; Rauch A; Salmon D; Lacombe K; Stewart A; Schinkel J; Doyle JS; Hellard M; van der Valk M; Matthews GV;
    Lancet Public Health; 2023 Apr; 8(4):e294-e304. PubMed ID: 36965984
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.